Trial Profile
A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-free Graft-versus-host Disease Prophylaxis Regimen With Post-transplantation Cyclophosphamide and Abatacept to Standard of Care
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Cyclophosphamide (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 19 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2022 Planned End Date changed from 1 Aug 2023 to 1 Dec 2027.
- 21 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2027.